Home / Health / Contineum Drug Trial Misses Key Efficacy Target
Contineum Drug Trial Misses Key Efficacy Target
25 Sep
Summary
- Contineum's partnered drug JNJ-5120/PIPE-307 failed its primary endpoint.
- The Phase 2 MOONLIGHT-1 study evaluated the drug for major depressive disorder.
- Johnson & Johnson is still analyzing remaining data before deciding on next steps.
Contineum Therapeutics, Inc. has reported that its partnered drug candidate, JNJ-5120/PIPE-307, did not meet the primary endpoint in a Phase 2 clinical trial. The MOONLIGHT-1 study, investigating the drug for major depressive disorder (MDD), failed to demonstrate sufficient efficacy. This result is a significant setback for investors anticipating positive outcomes.
The trial specifically assessed the drug's ability to alter Montgomery-Åsberg Depression Rating Scale (MADRS) scores within five days, targeting a rapid-acting treatment approach. While the primary efficacy goal was missed, the drug was reported as well-tolerated, with no new safety concerns arising during the trial.
Johnson & Johnson, which advanced the drug under a global license, is now conducting a thorough analysis of the remaining study data, including exploratory endpoints. The company has not yet discontinued the program, leaving its future prospects uncertain as they evaluate the complete dataset before making a final decision.
